Анемия хронических заболеваний: современное состояние проблемы и перспективы

1. Matzner Y, Levy S, Grossowicz N, et al. Prevalence and Causes of Anemia in Elderly Hospitalized Patients. Gerontology. 1979;25(2):113-9. DOI:10.1159/000212328
2. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev. 2002;16(2):87-96. DOI:10.1054/blre.2002.0193
3. Means Jr RT. Recent developments in the anemia of chronic disease. Curr Hematol Rep. 2003;2(2):116-21. 
4. World Health Organization. Noncommunicable diseases. Fact sheet. 2022. Available at: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases. Accessed: 02.06.2022.
5. Bernell S, Howard SW. Use your words carefully: what is a chronic disease? Front Public Heal. 2016;4:159. DOI:10.3389/fpubh.2016.00159
6. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23. DOI:10.1056/NEJMra041809
7. Dulmovits BM, Tang Y, Papoin J, et al. HMGB1-Mediated Restriction of EPO Signaling Contributes to Anemia of Inflammation. Blood. 2022;139(21):3181-93. DOI:10.1182/blood.2021012048
8. Yap GS, Stevenson MM. Inhibition of in vitro erythropoiesis by soluble mediators in Plasmodium chabaudi AS malaria: lack of a major role for interleukin 1, tumor necrosis factor alpha, and gamma interferon. Infect Immun. 1994;62(2):357-62.
9. Gordeuk VR, Delanghe JR, Langlois MR, Boelaert JR. Iron status and the outcome of HIV infection: an overview. J Clin Virol. 2001;20(3):111-5. DOI:10.1016/s1386-6532(00)00134-7
10. Fernández-García V, González-Ramos S, Avendaño-Ortiz J, et al. NOD1 splenic activation confers ferroptosis protection and reduces macrophage recruitment under pro-atherogenic conditions. Biomed Pharmacother. 2022;148:112769. DOI:10.1016/j.biopha.2022.112769
11. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-84. DOI:10.1038/ng.2996
12. De Domenico I, Ward DM, Langelier C, et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell. 2007;18(7):2569-78.
DOI:10.1091/mbc.e07-01-0060
13. Jiang L, Wang J, Wang K, et al. RNF217 regulates iron homeostasis through its E3 ubiquitin ligase activity by modulating ferroportin degradation. Blood. 2021;138(8):689-705. DOI:10.1182/blood.2020008986
14. Diepeveen LE, Stegemann G, Wiegerinck ET, et al. Investigating the Molecular Mechanisms of Renal Hepcidin Induction and Protection upon Hemoglobin-Induced Acute Kidney Injury. Int J Mol Sci. 2022;23(3):1352. DOI:10.3390/ijms23031352
15. Wieczorek M, Schwarz F, Sadlon A, et al. Iron deficiency and biomarkers of inflammation: A 3-year prospective analysis of the DO-HEALTH trial. Aging Clin Exp Res. 2022;34(3):515-25. DOI:10.1007/s40520-021-01955-3
16. Yağcı S, Serin E, Acicbe Ö, et al. The relationship between serum erythropoietin, hepcidin, and haptoglobin levels with disease severity and other biochemical values in patients with COVID-19. Int J Lab Hematol. 2021;43:142-51. DOI:10.1111/ijlh.13479
17. Zhou C, Chen Y, Ji Y, et al. Increased serum levels of hepcidin and ferritin are associated with severity of COVID-19. Med Sci Monit Int Med J Exp Clin Res. 2020;26:e926178-1. DOI:10.12659/MSM.926178
18. Zuin M, Rigatelli G, Quadretti L, et al. Prognostic Role of Anemia in COVID-19 Patients: A Meta-Analysis. Infect Dis Rep. 2021;13(4):930-7. DOI:10.3390/idr13040085
19. Chen Y, Xu W, Yang H, et al. Serum Levels of Hepcidin in Rheumatoid Arthritis and Its Correlation with Disease Activity and Anemia: A Meta-analysis. Immunol Invest. 2021;50(2-3):243-58. DOI:10.1080/08820139.2020.1742731
20. Szymczak A, Zalewska M, Rymer W, Jankowska EA. Asymptomatic Human Immunodeficiency Virus-1 Infection with High CD4+ T Cell Count Does Not Alter Iron Metabolism or Hepcidin Levels: The Pilot Study. Infect Dis Ther. 2022;11(1):265-75. DOI:10.1007/s40121-021-00560-1
21. Blindar VN, Dobrovolskaya MM, Khagazheeva MN, et al. The role of interleukin-6 and hepcidin 25 in the pathogenesis of anemic syndrome associated with malignant neoplasms with breast cancer patients before neoadjuvant chemotherapy. Klin Lab Diagn. 2021;66(3):147-53. DOI:10.51620/0869-2084-2021-66-3-147-153
22. Han J, Wang K. Clinical significance of serum hepcidin in the diagnosis and treatment of patients with anemia of chronic disease: a meta-analysis. Biomarkers. 2021;26(4):296-301. DOI:10.1080/1354750X.2021.1893812
23. Renders L, Budde K, Rosenberger C, et al. First-in-human Phase I studies of PRS-080# 22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. PLoS One. 2019;14(3):e0212023. DOI:10.1371/journal.pone.0212023
24. Boyce M, Warrington S, Cortezi B, et al. Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects. Br J Pharmacol. 2016;173(10):1580-8. DOI:10.1111/bph.13433
25. van Eijk LT, John ASE, Schwoebel F, et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood. 2014;124(17):2643-6. DOI:10.1182/blood-2014-03-559484
26. Macdougall IC, Rumjon A, Cinco J, et al. FP660 Pharmacokinetics and Pharmacodynamics of Lexaptepid, a Novel Anti-Hepcidin Molecule, in ESA-Resistant Haemodialysis Patients. Nephrol Dial Transplanation. 2015;30(suppl_3):iii294-5.
27. Vadhan-Raj S, Abonour R, Goldman JW, et al. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017;10(1):1-12. DOI:10.1186/s13045-017-0427-x
28. Sakamoto S, Kirinashizawa M, Mohara Y, Watanabe Y. Generation and characterization of monoclonal antibodies against mature hepcidin and its application to neutralization and quantitative alteration assay. Biosci Biotechnol Biochem. 2021;85(2):340-50. DOI:10.1093/bbb/zbaa013
29. Than MM, Koonyosying P, Ruangsuriya J, et al. Effect of Recombinant Human Erythroferrone Protein on Hepcidin Gene (Hamp1) Expression in HepG2 and HuH7 Cells. Materials (Basel). 2021;14(21):6480. DOI:10.3390/ma14216480
30. Lugus JJ, Park C, Ma YD, Choi K. Both primitive and definitive blood cells are derived from Flk-1+ mesoderm. Blood. 2009;113(3):563-6. DOI:10.1182/blood-2008-06-162750
31. Sidiartha IGL, Bakta IM, Wiryana IM, et al. Eicosapentaenoic acid and docosahexaenoic acid in fish oil capsule supplementation in obese children decreases serum interleukin-6 and hepcidin and improves iron status. Bali Med J. 2017;6(1):97-101. 
32. Lainé F, Laviolle B, Bardou-Jacquet E, et al. Curcuma decreases serum hepcidin levels in healthy volunteers: a placebo-controlled, randomized, double-blind, cross-over study. Fundam Clin Pharmacol. 2017;31(5):567-73. DOI:10.1111/fcp.12288
33. Barrington P, Sheetz MJ, Callies S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-ferroportin antibody in patients with anemia due to chronic renal failure. Blood. 2016;128(22):1280.
34. Isaacs JD, Harari O, Kobold U, et al. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther. 2013;15(6):1-6. DOI:10.1186/ar4397
35. Song SNJ, Iwahashi M, Tomosugi N, et al. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res Ther. 2013;15(5):1-10. DOI:10.1186/ar4323
36. Loza M, Campbell K, Sweet K, et al. FRI0243 Sirukumab treatment reduces levels of iron-regulatory proteins and ameliorates inflammation-associated anemia in rheumatoid arthritis patients. BMJ Publishing Group Ltd, 2017. 
37. Vallurupalli M, MacFadyen JG, Glynn RJ, et al. Effects of interleukin-1β inhibition on incident anemia: exploratory analyses from a randomized trial. Ann Intern Med. 2020;172(8):523-32. DOI:10.7326/M19-2945
38. Scarozza P, De Cristofaro E, Scucchi L, et al. Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases. J Clin Med. 2020;9(7):2126. DOI:10.3390/jcm9072126
39. Ghanim H, Abuaysheh S, Hejna J, et al. Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab. 2020;105(4):e1056-63. DOI:10.1210/clinem/dgaa057
40. Zheng L, Tian J, Liu D, et al. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(3):919-32. DOI:10.1111/bcp.15055
41. Xiong L, Zhang H, Guo Y, et al. Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021;12:795214. DOI:10.3389/fphar.2021.795214
42. Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197-210. DOI:10.1182/bloodadvances.2018030387
43. Анемия при злокачественных новообразованиях. Клинические рекомендации Минздрава РФ. М., 2022 [Anemiia pri zlokachestvennykh novoobrazovaniiakh. Klinicheskiie rekomendatsii Minzdrava RF. Moscow, 2022 (in Russian)].
44. Neoh K, Page A, Chin-Yee N, et al. Practice review: Evidence-based and effective management of anaemia in palliative care patients. Palliat Med. 2022;02692163221081967. DOI:10.1177/02692163221081967
45. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohn’s Colitis. 2015;9(3):211-22. DOI:10.1093/ecco-jcc/jju009
46. Анемия при хронической болезни почек. Клинические рекомендации Минздрава РФ. 2022. Режим доступа: https://cr.minzdrav.gov.ru/schema/623_4. Ссылка активна на 02.06.2022 [Anemiia pri khronicheskoi bolezni pochek. Klinicheskie rekomendatsii Minzdrava RF. 2022. Available at: https://cr.minzdrav.gov.ru/schema/623_4. Accessed: 02.06.2022 (in Russian)].
47. Sierpinski R, Josiak K, Suchocki T, et al. High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. Eur J Heart Fail. 2021;23(6):919-32. DOI:10.1002/ejhf.2036
48. Fitzsimons S, Poppe KK, Choi Y, et al. Relationship between soluble transferrin receptor and clinical outcomes in patients with Heart Failure According to Ejection Fraction Phenotype: The New Zealand PEOPLE Study. J Card Fail. 2022;28(8):1255-63. DOI:10.1016/j.cardfail.2021.12.018
49. Punnonen K, Irjala K, Rajamäki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89(3):1052-7. 
50. Fletcher A, Forbes A, Svenson N, et al. Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children. Br J Haematol. 2021;196(3):523-9. DOI:10.1111/bjh.17900
51. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998;91(1):301-8. 
52. Nissenson AR, Goodnough LT, Dubois RW. Anemia: not just an innocent bystander? Arch Intern Med. 2003;163(12):1400-4. DOI:10.1001/archinte.163.12.1400
53. Harrison L, Shasha D, Shiaova L, et al. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol. 2001:54-9. 
54. Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994;84(4):1056-63.
55. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002;100(7):2303-20. DOI:10.1182/blood-2002-06-1767
56. Gasche C, Waldhoer T, Feichtenschlager T, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 2001;96(8):2382-7. DOI:10.1111/j.1572-0241.2001.04094.x
57. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004;116(7):44-9. DOI:10.1016/j.amjmed.2003.12.011
58. Müller HM, Horina JH, Kniepeiss D, et al. Characteristics and clinical relevance of chronic anemia in adult heart transplant recipients. Clin Transplant. 2001;15(5):343-8. DOI:10.1034/j.1399-0012.2001.150507.x
59. Maheshwari A, Mishra R, Thuluvath PJ. Post-liver-transplant anemia: Etiology and management. Liver Transplant. 2004;10(2):165-73. DOI:10.1002/lt.20031
60. Collins AJ, Li S, Peter WST, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12(11):2465-73. DOI:10.1681/ASN.V12112465
61. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19(1):121-32. DOI:10.1093/ndt/gfg458
62. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant. 2001;16(suppl_7):36-40. DOI:10.1093/ndt/16.suppl_7.36
63. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem. 2002;48(7):1066-76
64. Ermens AA, Hoffmann JJ, Krockenberger M, Van Wijk EM. New erythrocyte and reticulocyte parameters on CELL-DYN Sapphire: analytical and preanalytical aspects. Int J Lab Hematol. 2012;34(3):274-82. DOI:10.1111/j.1751-553X.2011.01391.x 
65. Urrechaga E, Borque L, Escanero JF. Percentage of hypochromic erythrocytes as a potential marker of iron availability. Clin Chem Lab Med. 2011;50(4):685-7. DOI:10.1515/cclm.2011.837
66. Urrechaga E, Unceta M, Borque L, Escanero JF. Low hemoglobin density potential marker of iron availability. Int J Lab Hematol. 2012;34(1):47-51.
DOI:10.1111/j.1751-553X.2011.01355.x 
67. Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol. 2006;28(5):303-8.
DOI:10.1111/j.1365-2257.2006.00812.x 
68. Buttarello M, Rauli A, Mezzapelle G. Reticulocyte count and extended reticulocyte parameters by Mindray BC-6800: Reference intervals and comparison with Sysmex XE-5000. Int J Lab Hematol. 2017;39(6):596-603. DOI:10.1111/ijlh.12705

________________________________________________

1. Matzner Y, Levy S, Grossowicz N, et al. Prevalence and Causes of Anemia in Elderly Hospitalized Patients. Gerontology. 1979;25(2):113-9. DOI:10.1159/000212328
2. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev. 2002;16(2):87-96. DOI:10.1054/blre.2002.0193
3. Means Jr RT. Recent developments in the anemia of chronic disease. Curr Hematol Rep. 2003;2(2):116-21. 
4. World Health Organization. Noncommunicable diseases. Fact sheet. 2022. Available at: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases. Accessed: 02.06.2022.
5. Bernell S, Howard SW. Use your words carefully: what is a chronic disease? Front Public Heal. 2016;4:159. DOI:10.3389/fpubh.2016.00159
6. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23. DOI:10.1056/NEJMra041809
7. Dulmovits BM, Tang Y, Papoin J, et al. HMGB1-Mediated Restriction of EPO Signaling Contributes to Anemia of Inflammation. Blood. 2022;139(21):3181-93. DOI:10.1182/blood.2021012048
8. Yap GS, Stevenson MM. Inhibition of in vitro erythropoiesis by soluble mediators in Plasmodium chabaudi AS malaria: lack of a major role for interleukin 1, tumor necrosis factor alpha, and gamma interferon. Infect Immun. 1994;62(2):357-62.
9. Gordeuk VR, Delanghe JR, Langlois MR, Boelaert JR. Iron status and the outcome of HIV infection: an overview. J Clin Virol. 2001;20(3):111-5. DOI:10.1016/s1386-6532(00)00134-7
10. Fernández-García V, González-Ramos S, Avendaño-Ortiz J, et al. NOD1 splenic activation confers ferroptosis protection and reduces macrophage recruitment under pro-atherogenic conditions. Biomed Pharmacother. 2022;148:112769. DOI:10.1016/j.biopha.2022.112769
11. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-84. DOI:10.1038/ng.2996
12. De Domenico I, Ward DM, Langelier C, et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell. 2007;18(7):2569-78.
DOI:10.1091/mbc.e07-01-0060
13. Jiang L, Wang J, Wang K, et al. RNF217 regulates iron homeostasis through its E3 ubiquitin ligase activity by modulating ferroportin degradation. Blood. 2021;138(8):689-705. DOI:10.1182/blood.2020008986
14. Diepeveen LE, Stegemann G, Wiegerinck ET, et al. Investigating the Molecular Mechanisms of Renal Hepcidin Induction and Protection upon Hemoglobin-Induced Acute Kidney Injury. Int J Mol Sci. 2022;23(3):1352. DOI:10.3390/ijms23031352
15. Wieczorek M, Schwarz F, Sadlon A, et al. Iron deficiency and biomarkers of inflammation: A 3-year prospective analysis of the DO-HEALTH trial. Aging Clin Exp Res. 2022;34(3):515-25. DOI:10.1007/s40520-021-01955-3
16. Yağcı S, Serin E, Acicbe Ö, et al. The relationship between serum erythropoietin, hepcidin, and haptoglobin levels with disease severity and other biochemical values in patients with COVID-19. Int J Lab Hematol. 2021;43:142-51. DOI:10.1111/ijlh.13479
17. Zhou C, Chen Y, Ji Y, et al. Increased serum levels of hepcidin and ferritin are associated with severity of COVID-19. Med Sci Monit Int Med J Exp Clin Res. 2020;26:e926178-1. DOI:10.12659/MSM.926178
18. Zuin M, Rigatelli G, Quadretti L, et al. Prognostic Role of Anemia in COVID-19 Patients: A Meta-Analysis. Infect Dis Rep. 2021;13(4):930-7. DOI:10.3390/idr13040085
19. Chen Y, Xu W, Yang H, et al. Serum Levels of Hepcidin in Rheumatoid Arthritis and Its Correlation with Disease Activity and Anemia: A Meta-analysis. Immunol Invest. 2021;50(2-3):243-58. DOI:10.1080/08820139.2020.1742731
20. Szymczak A, Zalewska M, Rymer W, Jankowska EA. Asymptomatic Human Immunodeficiency Virus-1 Infection with High CD4+ T Cell Count Does Not Alter Iron Metabolism or Hepcidin Levels: The Pilot Study. Infect Dis Ther. 2022;11(1):265-75. DOI:10.1007/s40121-021-00560-1
21. Blindar VN, Dobrovolskaya MM, Khagazheeva MN, et al. The role of interleukin-6 and hepcidin 25 in the pathogenesis of anemic syndrome associated with malignant neoplasms with breast cancer patients before neoadjuvant chemotherapy. Klin Lab Diagn. 2021;66(3):147-53. DOI:10.51620/0869-2084-2021-66-3-147-153
22. Han J, Wang K. Clinical significance of serum hepcidin in the diagnosis and treatment of patients with anemia of chronic disease: a meta-analysis. Biomarkers. 2021;26(4):296-301. DOI:10.1080/1354750X.2021.1893812
23. Renders L, Budde K, Rosenberger C, et al. First-in-human Phase I studies of PRS-080# 22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. PLoS One. 2019;14(3):e0212023. DOI:10.1371/journal.pone.0212023
24. Boyce M, Warrington S, Cortezi B, et al. Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects. Br J Pharmacol. 2016;173(10):1580-8. DOI:10.1111/bph.13433
25. van Eijk LT, John ASE, Schwoebel F, et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood. 2014;124(17):2643-6. DOI:10.1182/blood-2014-03-559484
26. Macdougall IC, Rumjon A, Cinco J, et al. FP660 Pharmacokinetics and Pharmacodynamics of Lexaptepid, a Novel Anti-Hepcidin Molecule, in ESA-Resistant Haemodialysis Patients. Nephrol Dial Transplanation. 2015;30(suppl_3):iii294-5.
27. Vadhan-Raj S, Abonour R, Goldman JW, et al. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017;10(1):1-12. DOI:10.1186/s13045-017-0427-x
28. Sakamoto S, Kirinashizawa M, Mohara Y, Watanabe Y. Generation and characterization of monoclonal antibodies against mature hepcidin and its application to neutralization and quantitative alteration assay. Biosci Biotechnol Biochem. 2021;85(2):340-50. DOI:10.1093/bbb/zbaa013
29. Than MM, Koonyosying P, Ruangsuriya J, et al. Effect of Recombinant Human Erythroferrone Protein on Hepcidin Gene (Hamp1) Expression in HepG2 and HuH7 Cells. Materials (Basel). 2021;14(21):6480. DOI:10.3390/ma14216480
30. Lugus JJ, Park C, Ma YD, Choi K. Both primitive and definitive blood cells are derived from Flk-1+ mesoderm. Blood. 2009;113(3):563-6. DOI:10.1182/blood-2008-06-162750
31. Sidiartha IGL, Bakta IM, Wiryana IM, et al. Eicosapentaenoic acid and docosahexaenoic acid in fish oil capsule supplementation in obese children decreases serum interleukin-6 and hepcidin and improves iron status. Bali Med J. 2017;6(1):97-101. 
32. Lainé F, Laviolle B, Bardou-Jacquet E, et al. Curcuma decreases serum hepcidin levels in healthy volunteers: a placebo-controlled, randomized, double-blind, cross-over study. Fundam Clin Pharmacol. 2017;31(5):567-73. DOI:10.1111/fcp.12288
33. Barrington P, Sheetz MJ, Callies S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-ferroportin antibody in patients with anemia due to chronic renal failure. Blood. 2016;128(22):1280.
34. Isaacs JD, Harari O, Kobold U, et al. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther. 2013;15(6):1-6. DOI:10.1186/ar4397
35. Song SNJ, Iwahashi M, Tomosugi N, et al. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res Ther. 2013;15(5):1-10. DOI:10.1186/ar4323
36. Loza M, Campbell K, Sweet K, et al. FRI0243 Sirukumab treatment reduces levels of iron-regulatory proteins and ameliorates inflammation-associated anemia in rheumatoid arthritis patients. BMJ Publishing Group Ltd, 2017. 
37. Vallurupalli M, MacFadyen JG, Glynn RJ, et al. Effects of interleukin-1β inhibition on incident anemia: exploratory analyses from a randomized trial. Ann Intern Med. 2020;172(8):523-32. DOI:10.7326/M19-2945
38. Scarozza P, De Cristofaro E, Scucchi L, et al. Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases. J Clin Med. 2020;9(7):2126. DOI:10.3390/jcm9072126
39. Ghanim H, Abuaysheh S, Hejna J, et al. Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab. 2020;105(4):e1056-63. DOI:10.1210/clinem/dgaa057
40. Zheng L, Tian J, Liu D, et al. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(3):919-32. DOI:10.1111/bcp.15055
41. Xiong L, Zhang H, Guo Y, et al. Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021;12:795214. DOI:10.3389/fphar.2021.795214
42. Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197-210. DOI:10.1182/bloodadvances.2018030387
43. Анемия при злокачественных новообразованиях. Клинические рекомендации Минздрава РФ. М., 2022 [Anemiia pri zlokachestvennykh novoobrazovaniiakh. Klinicheskiie rekomendatsii Minzdrava RF. Moscow, 2022 (in Russian)].
44. Neoh K, Page A, Chin-Yee N, et al. Practice review: Evidence-based and effective management of anaemia in palliative care patients. Palliat Med. 2022;02692163221081967. DOI:10.1177/02692163221081967
45. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohn’s Colitis. 2015;9(3):211-22. DOI:10.1093/ecco-jcc/jju009
46. Anemiia pri khronicheskoi bolezni pochek. Klinicheskie rekomendatsii Minzdrava RF. 2022. Available at: https://cr.minzdrav.gov.ru/schema/623_4. Accessed: 02.06.2022 (in Russian).
47. Sierpinski R, Josiak K, Suchocki T, et al. High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. Eur J Heart Fail. 2021;23(6):919-32. DOI:10.1002/ejhf.2036
48. Fitzsimons S, Poppe KK, Choi Y, et al. Relationship between soluble transferrin receptor and clinical outcomes in patients with Heart Failure According to Ejection Fraction Phenotype: The New Zealand PEOPLE Study. J Card Fail. 2022;28(8):1255-63. DOI:10.1016/j.cardfail.2021.12.018
49. Punnonen K, Irjala K, Rajamäki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89(3):1052-7. 
50. Fletcher A, Forbes A, Svenson N, et al. Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children. Br J Haematol. 2021;196(3):523-9. DOI:10.1111/bjh.17900
51. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998;91(1):301-8. 
52. Nissenson AR, Goodnough LT, Dubois RW. Anemia: not just an innocent bystander? Arch Intern Med. 2003;163(12):1400-4. DOI:10.1001/archinte.163.12.1400
53. Harrison L, Shasha D, Shiaova L, et al. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol. 2001:54-9. 
54. Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994;84(4):1056-63.
55. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002;100(7):2303-20. DOI:10.1182/blood-2002-06-1767
56. Gasche C, Waldhoer T, Feichtenschlager T, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 2001;96(8):2382-7. DOI:10.1111/j.1572-0241.2001.04094.x
57. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004;116(7):44-9. DOI:10.1016/j.amjmed.2003.12.011
58. Müller HM, Horina JH, Kniepeiss D, et al. Characteristics and clinical relevance of chronic anemia in adult heart transplant recipients. Clin Transplant. 2001;15(5):343-8. DOI:10.1034/j.1399-0012.2001.150507.x
59. Maheshwari A, Mishra R, Thuluvath PJ. Post-liver-transplant anemia: Etiology and management. Liver Transplant. 2004;10(2):165-73. DOI:10.1002/lt.20031
60. Collins AJ, Li S, Peter WST, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12(11):2465-73. DOI:10.1681/ASN.V12112465
61. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19(1):121-32. DOI:10.1093/ndt/gfg458
62. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant. 2001;16(suppl_7):36-40. DOI:10.1093/ndt/16.suppl_7.36
63. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem. 2002;48(7):1066-76
64. Ermens AA, Hoffmann JJ, Krockenberger M, Van Wijk EM. New erythrocyte and reticulocyte parameters on CELL-DYN Sapphire: analytical and preanalytical aspects. Int J Lab Hematol. 2012;34(3):274-82. DOI:10.1111/j.1751-553X.2011.01391.x 
65. Urrechaga E, Borque L, Escanero JF. Percentage of hypochromic erythrocytes as a potential marker of iron availability. Clin Chem Lab Med. 2011;50(4):685-7. DOI:10.1515/cclm.2011.837
66. Urrechaga E, Unceta M, Borque L, Escanero JF. Low hemoglobin density potential marker of iron availability. Int J Lab Hematol. 2012;34(1):47-51.
DOI:10.1111/j.1751-553X.2011.01355.x 
67. Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol. 2006;28(5):303-8.
DOI:10.1111/j.1365-2257.2006.00812.x 
68. Buttarello M, Rauli A, Mezzapelle G. Reticulocyte count and extended reticulocyte parameters by Mindray BC-6800: Reference intervals and comparison with Sysmex XE-5000. Int J Lab Hematol. 2017;39(6):596-603. DOI:10.1111/ijlh.12705

О.Ю. Миронова*, А.С. Панферов

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*mironova_o_yu@staff.sechenov.ru

________________________________________________

Olga Iu. Mironova*, Alexandr S. Panferov

Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*mironova_o_yu@staff.sechenov.ru